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Combining drug-loaded nanobubbles and Extracorporeal Shock Waves for difficult-to-treat 
cancers 
Despite the general great improvement in cancer therapy, to date, some aggressive tumors are still 
without an efficient therapy. Therefore, accurate delivery of anti-cancer drugs is a very important 
goal in order to obtain a successful therapy and reduce systemic side effects.  
Nanobubbles (NBs) are spherical core/shell vesicles filled by a gas with sizes in the nanometer 
order of magnitude. They have gained an increasing attention for drug delivery, because they can be 
versatile multifunctional carriers for the targeted release of gases, drugs and genes.  Particularly, 
NBs can carry loaded drugs to the tumor site through the blood stream, taking advantage of the 
enhanced permeability and retention effect, due to the defective vascular architecture of the tumor 
(Fang et al. 2011). Unfortunately, vessel leakage, the absence of a functional lymphatic system and 
an increased extracellular matrix frictional resistance may limit drug delivery (Azzi et al. 2013, 
Carmeliet and Jain 2011). To overcome this problem, a better drug release to cancer tissues can be 
obtained by combining physical triggers (e.g. ultrasounds, US) with NBs (Gao et al. 2008, Collis et 
al. 2010, Cavalli et al. 2012, Cavalli et al. 2016). Indeed, US causes bubble cavitation resulting in 
cell sonoporation and allowing the extravasation of molecules (Collis et al. 2010).  
Interestingly, polysaccharide-shelled perfloropentane (PFP)-cored NBs were developed for the 
delivery of anticancer agents displaying good drug encapsulation efficiency and a prolonged release 
kinetics. This type of formulation is referred to as “nanobubbles” for sake of simplicity but it must 
be said that, prior to the application of external stimuli such as US, it would be more accurate to use 
the term “nanodroplets” when the core is constituted of PFP, being a perfluorocarbon liquid at room 
temperature (boiling point 29 °C) (Cavalli et al. 2015). 
Extracorporeal Shock Waves (ESWs), introduced in medicine about 40 years ago (Eisenberger et al. 
1978), are short-duration (<10 μs) focused acoustic waves consisting of a compressive phase (peak 
pressure: 10–100 MPa) followed by a tensile phase (negative pressure). ESW therapy is widely 
used in urology for lithotripsy to break urinary stones (Rassweiler et al. 2011). In addition to 
lithotripsy, more recently, ESWs have been successfully used for the treatment of several 
musculoskeletal diseases (Wang et al. 2012). ESWs can be focused with high precision also in 
depth and they determine permeabilization of plasma membranes (Frairia et al. 2003, Catalano et al. 
2007), as a consequence of cavitation occurring when shockwaves propagate into fluids. As result 
of induced cell permeability, ESWs increase the cytotoxic effects of different anti-cancer drugs 
(Frairia et al. 2003, Palmero et al. 2006, Catalano et al. 2007, Canaparo et al. 2008). Notably, ESWs 
differ from US as they have 1000 times higher peak pressure (Wang et al. 2012), and no heating 
effects. The absence of heating effect is an advantage for in vivo application since temperature 
elevation is difficult to control spatially and temporally, especially in large tumors with 
heterogeneous vascularization (Diederich et al. 1999). All these features make ESWs an ideal tool 
to be used in combination with drug-loaded NBs. Indeed, drug-loaded NBs can be injected 
intravenously and, when they have reached the tumor, ESWs can be applied directly at the tumor 
site. At this level, in fact, ESW-induced cavitation might determine perturbation of the NBs in 
addition to transient permeabilization of both plasma and nuclear membranes, resulting in the drug 
release and penetration into the cells.  
The effects of combining chemotherapeutic drug-loaded NBs and ESWs have been recently 
investigated into two different types of aggressive cancers; e.g., anaplastic thyroid cancer (ATC) 
and castration resistant prostate cancer (CRPC).  
In ATC, we obtained both in vitro and in vivo data. In vitro, the combined treatment with 
doxorubicin-loaded glycol chitosan NBs and ESWs enhanced cytotoxicity of doxorubicin in two 
different ATC cells lines (CAL-62 and 8305C), decreasing the drug growth inhibition fifty (GI50) of 
40% in CAL-62 and 46% in 8305C cells, respectively (Marano et al. 2016). The reduction of the 
GI50 is notable, since the use of lower doses of doxorubicin is essential to reduce its side effects. In 
a xenograft in vivo model, after 21 days, the combined treatment determined the greatest drug 
accumulation in tumors with consequent reduction of tumor volume and weight, and an extension 
of the tumor doubling time. Mechanistically, the treatment induced tumor apoptosis and decreased 
cell proliferation. Finally, loading doxorubicin into NBs avoided and prevented heart damage, the 
most frequent side effect of the free drug that causes heart fibrosis and oxidative stress (Marano et 
al. 2017).  
In CRPC, Marano et al. (2016) reported that the combined treatment with either paclitaxel- or 
docetaxel-loaded NBs and ESWs enhanced the cytotoxicity of both taxanes in two different cell 
lines (PC3 and DU145), resulting in paclitaxel GI50 reduction of about 55% and in docetaxel GI50 
reduction of about 45%, respectively. Moreover, the proposed combination therapy was effective 
also on cell migration. Paclitaxel-loaded NBs and ESWs reduced cell migration by more than 85% 
with respect to paclitaxel alone; whereas docetaxel-loaded NBs and ESWs reduced cell migration 
by more than 82 % with respect to docetaxel alone. 
Given the promising results of these preclinical studies, combining drug-loaded NBs and ESWs 
should be taken into account also for other aggressive tumors in which chemotherapy remains the 
first option. The next step will be conducting clinical trials with the hope of improving cancer 
treatment as well as patient quality of life. 
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